Ropes & Gray advised Monte Rosa Therapeutics on the transaction. Monte Rosa Therapeutics (Nasdaq: GLUE) has entered into a global exclusive licensing agreement with Novartis to...
Monte Rosa Therapeutics’ Global Licensing Collaboration with Novartis
Monte Rosa Therapeutics’ $100 Million Underwritten Public Offering
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
Monte Rosa Therapeutics’ $95 Million Series C Financing
Goodwin Procter LLP advised Monte Rosa Therapeutics on the deal. Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing...